BSH 2022 | The importance of MRD monitoring in AML
Peter Valk
• 1 Apr 2022
Peter Valk, PhD, Erasmus University Medical Center, Rotterdam, Netherlands, discusses the importance of measurable residual disease (MRD) monitoring in acute myeloid leukemia (AML). Dr Valk briefly explains how flow cytometry and molecular analyses are used in MRD monitoring and further compares the use of these methods in a clinical setting. To conclude, Dr Valk mentions novel approaches to MRD monitoring, drawing focus on the application of next-generation sequencing (NGS)-based methods. This interview took place at the 62nd Annual Scientific Meeting of the British Society for Haematology (BSH) 2022, in Manchester, UK.
